Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans.
Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans.
复制标题
血清 - 神经1-磷酸盐浓度与人类的动脉粥样硬化疾病成反比。
DOI：
10.1371/journal.pone.0168302
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Daum G
中科院分区：
文献类型：
--
作者：
Soltau I;Mudersbach E;Geissen M;Schwedhelm E;Winkler MS;Geffken M;Peine S;Schoen G;Debus ES;Larena-Avellaneda A;Daum G
动脉粥样硬化性病变是心血管疾病死亡的主要原因，严重影响患者的生活质量。鞘氨醇-1-磷酸（S1 P）是一种信号鞘脂，可调节潜在的促动脉粥样硬化和抗动脉粥样硬化过程。在这里，我们调查是否血清S1 P浓度与外周动脉疾病（PAD）和颈动脉狭窄（CS）。从献血者（对照组，N = 174）和动脉粥样硬化患者（N = 132）中采集血清样本，这些患者因临床相关PAD（N = 102）或CS（N = 30）就诊。从所有受试者，血清S1 P测定质谱和血液参数进行了测定，通过常规实验室检测。与对照组相比，动脉粥样硬化患者在进行侵入性治疗以恢复血流之前，血清S1 P水平显着降低。这种差异不能用动脉粥样硬化（老年、男性、高血压、高血脂、肥胖、糖尿病或吸烟）或合并症（慢性阻塞性肺疾病、肾功能不全或心律失常）的风险因素来解释。受试者工作特征曲线表明，S1 P比高密度脂蛋白胆固醇（HDL-C）更有能力指示动脉粥样硬化（PAD和CS）。在35例患者中，在治疗后1至6个月再次测量血清S1 P。在该组中，血清S1 P浓度在治疗后升高，与患者是否患有PAD或CS，或是否接受开放或血管内手术无关。治疗后S1 P水平与治疗前测量的血小板数量高度相关。我们的研究表明，PAD和CS在人类与血清S1 P浓度降低，S1 P可能具有更高的准确性，以指示这些疾病比HDL-C。
Atherosclerotic changes of arteries are the leading cause for deaths in cardiovascular disease and greatly impair patient’s quality of life. Sphingosine-1-phosphate (S1P) is a signaling sphingolipid that regulates potentially pro-as well as anti-atherogenic processes. Here, we investigate whether serum-S1P concentrations are associated with peripheral artery disease (PAD) and carotid stenosis (CS). Serum was sampled from blood donors (controls, N = 174) and from atherosclerotic patients (N = 132) who presented to the hospital with either clinically relevant PAD (N = 102) or CS (N = 30). From all subjects, serum-S1P was measured by mass spectrometry and blood parameters were determined by routine laboratory assays. When compared to controls, atherosclerotic patients before invasive treatment to restore blood flow showed significantly lower serum-S1P levels. This difference cannot be explained by risk factors for atherosclerosis (old age, male gender, hypertension, hypercholesteremia, obesity, diabetes or smoking) or comorbidities (Chronic obstructive pulmonary disease, kidney insufficiency or arrhythmia). Receiver operating characteristic curves suggest that S1P has more power to indicate atherosclerosis (PAD and CS) than high density lipoprotein-cholesterol (HDL-C). In 35 patients, serum-S1P was measured again between one and six months after treatment. In this group, serum-S1P concentrations rose after treatment independent of whether patients had PAD or CS, or whether they underwent open or endovascular surgery. Post-treatment S1P levels were highly associated to platelet numbers measured pre-treatment. Our study shows that PAD and CS in humans is associated with decreased serum-S1P concentrations and that S1P may possess higher accuracy to indicate these diseases than HDL-C.